To the full analysis
Buyback calculator for Nutex Health
Nutex Health stock: key metrics
NUTXNutex Health had an operating margin of 31.5% and a return on invested capital (ROIC) of 37.3% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2008 | no data | no data | no data |
| 2009 | 56.9% | −310.2% | no data |
| 2010 | 38.2% | −106.3% | no data |
| 2011 | 40.0% | −33.1% | −15.0% |
| 2012 | 50.8% | −91.7% | −101.9% |
| 2013 | 66.1% | −49.8% | no data |
| 2014 | 56.5% | −73.0% | −64.0% |
| 2015 | no data | no data | no data |
| 2016 | no data | no data | no data |
| 2017 | −2,336.2% | −10,165.0% | 2,512.6% |
| 2018 | 62.8% | −61.5% | −205.9% |
| 2019 | 58.6% | 35.8% | 21.6% |
| 2020 | 57.5% | 55.9% | 38.7% |
| 2021 | 54.1% | 51.4% | 40.0% |
| 2022 | 7.0% | −185.4% | −193.7% |
| 2023 | 14.0% | −12.8% | −18.5% |
| 2024 | 40.9% | 27.2% | 10.9% |
| 2025 | 50.8% | 31.5% | 8.1% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2008 | no data | −24.6% | no data |
| 2009 | no data | −67.6% | no data |
| 2010 | no data | −85.6% | no data |
| 2011 | −23.9% | −46.1% | −18.5% |
| 2012 | −100.0% | no data | −100.0% |
| 2013 | no data | no data | no data |
| 2014 | 200.0% | no data | −100.0% |
| 2015 | 5.4% | −54.1% | 1.1% |
| 2016 | no data | no data | no data |
| 2017 | 24.6% | no data | 17.5% |
| 2018 | 187.9% | −52.9% | −100.0% |
| 2019 | 73.9% | 42.7% | 11.7% |
| 2020 | 123.5% | 70.4% | 34.3% |
| 2021 | 115.6% | 55.9% | 33.6% |
| 2022 | −100.0% | −93.5% | −98.4% |
| 2023 | −74.5% | −7.3% | −11.5% |
| 2024 | 35.7% | 27.3% | 8.0% |
| 2025 | 21.5% | 37.3% | 7.7% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.